Oncology – Medxy AI

RETREAT Score Stratifies Long-Term Hepatocellular Carcinoma Recurrence Risk After Liver Transplantation in Real-World Practice

By MedXY 06/07/2026

A single-center validation study shows the RETREAT score reliably predicts long-term HCC recurrence after liver transplantation and identifies patients with markedly different recurrence-free and overall survival trajectories.

Hematology-Oncology news Oncology

First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial

By MedXY 06/07/2026

Extended follow-up from ASTRUM-005 shows serplulimab plus chemotherapy improves long-term survival in untreated extensive-stage small cell lung cancer, with manageable safety and encouraging patient-reported outcomes.

$Off-the-Shelf, Non-Gene-Edited Allogeneic CD19 CAR-T Cells Show Early Feasibility in Relapsed or Refractory B-ALL$

Hematology-Oncology news Oncology

Off-the-Shelf, Non-Gene-Edited Allogeneic CD19 CAR-T Cells Show Early Feasibility in Relapsed or Refractory B-ALL

By MedXY 06/06/2026

A phase 1 study suggests non-gene-edited allogeneic CD19 CAR-T therapy can induce remissions in relapsed or refractory B-ALL without observed GVHD, though durability remains limited and larger trials are needed.

news OB/GYN & Women’s Health Oncology

Tumor Morcellation, Not Minimally Invasive Surgery Alone, Drives Worse Disease-Free Survival in Stage I Adult Granulosa Cell and Sertoli-Leydig Cell Tumors

By MedXY 06/06/2026

In stage I ovarian sex cord-stromal tumors, stage IC and tumor morcellation were independently associated with recurrence, while minimally invasive surgery itself was not after adjustment.

Diabetes & Endocrinology news Oncology

Early HbA1c Control After Type 2 Diabetes Diagnosis May Shape Long-Term Cancer Risk

By MedXY 06/05/2026

In a large Hong Kong cohort with newly diagnosed type 2 diabetes, higher early HbA1c exposure was associated with greater long-term cancer risk, suggesting that glycaemic control soon after diagnosis may matter more than later improvement.

Gastroenterology news Oncology

Language Barriers and Treatment Delays Emerge as Modifiable Threats in Early-Onset Colorectal Cancer

By MedXY 06/05/2026

A large Texas registry study found that treatment delays beyond 6 weeks were independently associated with worse survival in early-onset colorectal cancer, with language barriers identified as a potentially modifiable contributor.

Hematology-Oncology news Oncology

S1P Receptor Modulation Restores FLT3 Inhibitor Sensitivity in NRAS-Mutated FLT3-ITD Acute Myeloid Leukemia

By MedXY 06/04/2026

Preclinical data suggest fingolimod and mocravimod can resensitize NRAS-mutated FLT3-ITD AML to FLT3 inhibitors by suppressing ERK-SPHK1-AKT signaling, including activity in patient blasts and an orthotopic mouse model.

news Oncology Ophthalmology

Immune Checkpoint Inhibitor-Associated Uveitis: Comparative Risk Across Cancers and Drug Classes

By MedXY 06/04/2026

A multicenter study found that immune checkpoint inhibitor–associated uveitis risk varies by cancer type and drug class, with melanoma showing the highest intrinsic risk and RCC risk largely linked to ipilimumab/nivolumab exposure.

news OB/GYN & Women’s Health Oncology

Transcriptome Profiling With CCNA2 and E2F1 May Identify Platinum Insensitivity and Refine Prognosis in Endometrial Cancer

By MedXY 06/04/2026

TCGA-based transcriptome analysis suggests high CCNA2 and E2F1 expression marks poor progression-free survival and probable platinum insensitivity in endometrial cancer, supporting pretreatment molecular stratification and alternative therapeutic selection.

Gastroenterology news Oncology

Y90 Radioembolization as a Bridge to Liver Transplantation in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

By MedXY 06/03/2026

Y90 radioembolization downstaged about one-quarter of HCC patients with portal vein tumor thrombosis to transplant eligibility, and those who received liver transplantation had markedly better cancer-related outcomes and survival.

Clinical Updates news Oncology

Adipocyte-Driven Immunometabolic Suppression in Pancreatic Cancer: The 12,13-DiHOME/PPARγ/TAN Axis

By MedXY 06/03/2026

This review explores how tumour-infiltrating adipocytes release 12,13-DiHOME to trigger neutrophil ferroptosis and CXCL2 production, ultimately subverting CD8+ T cell-mediated immunity in pancreatic ductal adenocarcinoma.

Gastroenterology news Oncology

Quorum-Sensing Molecules Elevated in Long-Standing Ulcerative Colitis May Help Drive Colitis-Associated Cancer

By MedXY 06/03/2026

Bacterial quorum-sensing molecules, especially C6-scAHL, were elevated in long-standing ulcerative colitis and promoted colon tumor growth in mice, suggesting a new microbiome-driven pathway for colitis-associated cancer.

Diabetes & Endocrinology news Oncology

Detectable Antithyroglobulin Antibodies Above the Assay LOQ Signal Higher Recurrence Risk in Papillary Thyroid Carcinoma Despite Undetectable Thyroglobulin

By MedXY 06/03/2026

In papillary thyroid carcinoma treated with thyroidectomy and RAI, TgAb levels above the assay’s limit of quantification identified patients with higher long-term recurrence risk despite undetectable serum thyroglobulin.

news OB/GYN & Women’s Health Oncology

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial

By MedXY 06/03/2026

Adding fovinaciclib to first-line aromatase inhibitor therapy significantly prolonged progression-free survival in hormone receptor-positive, ERBB2-negative advanced breast cancer with manageable toxicity and preserved quality of life.

$Twice-Weekly All-Oral Ixazomib, Pomalidomide, and Dexamethasone Shows Durable Activity in Relapsed/Refractory Multiple Myeloma$

Hematology-Oncology news Oncology

Twice-Weekly All-Oral Ixazomib, Pomalidomide, and Dexamethasone Shows Durable Activity in Relapsed/Refractory Multiple Myeloma

By MedXY 06/02/2026

A phase I/II study suggests twice-weekly ixazomib plus pomalidomide-dexamethasone is a feasible all-oral option in relapsed/refractory multiple myeloma, with a 65.8% response rate at the RP2D and manageable hematologic toxicity.

Hematology-Oncology news Oncology

Anti-CD117 Conditioning With Briquilimab Shows Feasibility and Stem-Cell Depletion in Older Adults Undergoing Allogeneic Transplant for High-Risk AML and MDS

By MedXY 06/02/2026

A phase 1 trial suggests briquilimab can be safely added to nonmyeloablative conditioning before allogeneic transplant in older adults with high-risk AML or MDS, with biologic evidence of hematopoietic stem/progenitor cell depletion and encouraging early survival outcomes.

Gastroenterology news Oncology

Pancreatic Cancer Risk During IPMN Surveillance Is About 10-Fold Higher Than in the General Population

By MedXY 06/01/2026

A SEER-matched analysis found that patients undergoing IPMN surveillance have a markedly elevated malignancy risk, with substantial heterogeneity by duct dilation, obesity, age, and cyst features.

Gastroenterology news Oncology

Pancreatic Cancer Risk During IPMN Surveillance: A SEER-Based Comparison

By MedXY 06/01/2026

A SEER-based study found IPMN surveillance patients have about 10 times higher pancreatic cancer risk than the general population, with highest risk in those with main duct dilation or obesity.

news OB/GYN & Women’s Health Oncology

More Than Half of Patients With Atypical Endometrial Hyperplasia Had Occult Cancer at Hysterectomy in a Minority-Enriched Urban Cohort

By MedXY 06/01/2026

A single-center retrospective study found unexpectedly high rates of concurrent endometrial carcinoma and Mayo-criteria risk features among patients with atypical endometrial hyperplasia in a predominantly racial and ethnic minority population.

news Oncology Psychiatry

Longitudinal Risk for Suicidal Self-Directed Violence Among Veterans With Cancer

By MedXY 05/31/2026

A national study of veterans with cancer found elevated suicide-related risk that persisted for years, especially among younger, unmarried, frail, or mentally ill patients and those with certain cancers such as central nervous system and thyroid tumors.